Baxter International BAX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Net Sales by Business | ||||||
| Healthcare Systems & Technologies | $3.07B+2.8% | $3.07B+4.1% | $3.03B+2.2% | $3.01B+1.8% | $2.99B+1.3% | |
| Medical Products & Therapies | $5.32B+1.6% | $5.3B+1.8% | $5.23B+0.2% | $5.24B+2.1% | $5.24B+3.1% | |
| Pharmaceuticals | $2.53B+4.9% | $2.49B+3.4% | $2.47B+4.4% | $2.42B+2.8% | $2.41B+4.7% | |
| Net Sales by Product | ||||||
| Advanced Surgery | $1.23B+11.3% | $1.2B+8.5% | $1.16B+6.6% | $1.13B+5.1% | $1.11B+3.8% | |
| Care & Connectivity Solutions | $1.92B+4.4% | $1.91B+5.3% | $1.88B+4.2% | $1.86B+4.0% | $1.84B+3.7% | |
| Drug Compounding | $1.22B+17.5% | $1.14B+9.9% | $1.09B+6.9% | $1.05B+7.8% | $1.03B+10.7% | |
| Front Line Care | $1.15B+0.3% | $1.16B+2.0% | $1.15B-0.8% | $1.15B-1.5% | $1.15B-2.2% | |
| Infusion Therapies & Technologies | $4.09B-1.0% | $4.1B0.0% | $4.06B-1.5% | $4.11B+1.3% | $4.13B+2.9% | |
| Injectables & Anesthesia | $1.32B-4.5% | $1.35B-1.5% | $1.38B+2.4% | $1.37B-0.7% | $1.38B+0.7% | |
| Net Sales by Geography | ||||||
| International | $5.25B+9.9% | $5.12B+7.0% | $4.94B+3.7% | $4.85B+3.2% | $4.78B-12.4% | |
| United States | $6.07B+1.3% | $6.12B+4.6% | $6.08B+4.1% | $6.04B+3.9% | $5.99B-1.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Baxter International break its business down?
- Baxter International (BAX) reports net sales by business across 3 parts — Healthcare Systems & Technologies, Medical Products & Therapies and Pharmaceuticals. Each is extracted from the segment footnotes and tracked over time.
- Where does Baxter International's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Baxter International's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
